FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:954-955 March 1, 2007 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Targeting drugs to tumors has been a key goal of cancer pharmacology for decades. Newer technologies such as monoclonal antibodies engineered to target tumors, as well as liposomal or nanoparticle drug carriers, represent important steps toward this goal, but they have limitations. A recent study by Cheong and colleagues¹ provides a new twist on tumor-targeted drugs: the authors use bacteria to release liposomal drugs within the tumor (Figure 1).

View larger version (64K):   Figure 1. Targeting Drugs to Tumors with Bacteria. Cheong et al.1 recently described a new strategy of targeting cancer using mouse models. Doxil (liposomal doxorubicin) is administered to tumor-bearing animals previously . . . [Full Text of this Article]

 

Source Information

From the Department of Pharmacology and the Carolina Center of Cancer Nanotechnology Excellence, School of Medicine, University of North Carolina, Chapel Hill.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.